Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Core Insights - Palisade Bio, Inc. is developing PALI-2108, the first and only PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon, addressing unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) [1][7] - The Crohn's & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade to support the clinical development of PALI-2108 [1][2] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at improving pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [5][6] - The company is advancing PALI-2108 for moderate-to-severe UC and FSCD, with a recent Phase 1b trial showing a 100% clinical response in the UC cohort and no serious adverse events [7][8] Product Development - PALI-2108 is designed for local delivery of PDE4 inhibition, becoming active only in the lower intestine, which minimizes systemic exposure and enhances therapeutic effects [3][7] - The company has completed several Phase 1 studies and is preparing for Phase 2 Investigational New Drug (IND) submissions to the FDA in 2026 [2][8]